Xeljanz (Psoriasis)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 13
3.2 Symptoms 16
4 Disease Management 17
4.1 Treatment Overview 18
5 Competitive Assessment 22
5.1 Overview 22
5.2 Strategic Competitor Assessment 23
6 Opportunity and Unmet Need 24
6.1 Overview 24
6.2 Unmet Needs 25
6.2.1 Improved Drug Safety and Efficacy Profiles 25
6.2.2 Biomarkers for Predicting Remission 26
6.2.3 More Cost-Effective Therapies Through Oral Formulation and Biosimilars 26
6.2.4 Education and Treatment of Psychological Factors Accompanying Psoriasis 27
6.2.5 An Effective Biologic/Systemic Topical Therapy 27
6.2.6 More Effective Treatment for Mild Psoriasis, Specifically UV Therapies 28
6.2.7 Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis 28
6.3 Opportunities 29
6.4 Unmet Needs Gap Analysis 29
6.4.1 Predictive Tools for Diagnosis and Treatment 30
6.4.2 Target Specificity 30
6.4.3 Topical Biologic/Systemic Therapeutic Options 31
6.4.4 Helping Patients with Psychological Issues Associated with Psoriasis 31
7 Pipeline Assessment 32
7.1 Overview 32
7.2 Promising Drugs in Clinical Development 33
8 Xeljanz (tofacitinib) 35
8.1 Overview 35
8.2 Efficacy 36
8.3 Safety 37
8.4 Dosing and Formulation 38
8.5 Potential Clinical Positioning 38
8.6 Potential Commercial Positioning 39
8.7 Pricing and Reimbursement 39
8.8 SWOT Analysis 40
8.9 Forecast 41
9 Appendix 43
9.1 Bibliography 43
9.2 Abbreviations 45
9.3 Methodology 48
9.4 Forecasting Methodology 48
9.4.1 Diagnosed Psoriasis Patients 48
9.4.2 Percent Drug-Treated Patients 49
9.4.3 General Pricing Assumptions 49
9.4.4 Generic Erosion 50
9.4.5 Pricing of Pipeline agents 50
9.5 Physicians and Specialists Included in this Study 51
9.6 Primary Research – Prescriber Survey 52
9.7 About the Authors 53
9.7.1 Analysts 53
9.7.2 Global Head of Healthcare 54
9.8 About GlobalData 55
9.9 Disclaimer 55